Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
Want to see BDRX full AI Analyst Report?
Top Page
Biodexa Pharmaceuticals
(NASDAQ:BDRX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$4.00
▲(71.67% Upside)
Action:ReiteratedDate:04/07/26
The score is held down primarily by ongoing losses, zero revenue, and continued cash burn despite improvement in 2025. Technicals also remain weak with negative MACD and the price below longer-term moving averages, while valuation is difficult to support due to a negative P/E and no dividend yield. The key positive is a low-debt balance sheet with increased equity, which partially mitigates funding risk.
Positive Factors
Low Leverage / Strong Balance Sheet
Biodexa's 2025 balance sheet shows minimal leverage and materially higher equity, giving financial flexibility to fund clinical programs. Low debt reduces refinancing risk and supports sustained R&D spending while trials advance toward readouts or partnering opportunities.
Negative Factors
No Product Revenue
Biodexa remains a pre-commercial biopharma with zero reported revenues, meaning operations and R&D cannot be self-funded by product sales. This structural dependence on external capital or partnerships increases dilution and execution risk if clinical timelines slip or market conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Biodexa's 2025 balance sheet shows minimal leverage and materially higher equity, giving financial flexibility to fund clinical programs. Low debt reduces refinancing risk and supports sustained R&D spending while trials advance toward readouts or partnering opportunities.
Read all positive factors
Biodexa Pharmaceuticals (BDRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.49M
Dividend YieldN/A
Average Volume (3M)260.97K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue GrowthN/A
EPS Growth88.07%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding648,314
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.09
Enterprise Value/Market Cap-5.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.70
Enterprise Value/Ebitda0.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Biodexa Pharmaceuticals Business Overview & Revenue Model
Company Description
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan canc...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Biodexa has historically not generated material recurring revenue from marketed pharmaceutical product sales (null). Its operations have primarily been funded through financing activities such as the ...
Biodexa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 381.00K | 699.00K | 578.00K |
| Gross Profit | -184.86K | -5.44M | -3.69M | -4.41M | -4.08M |
| EBITDA | -8.08M | -9.08M | -7.16M | -8.26M | -5.66M |
| Net Income | -6.24M | -5.73M | -7.08M | -7.66M | -5.46M |
Balance Sheet | |||||
| Total Assets | 18.15M | 14.78M | 10.54M | 5.53M | 12.91M |
| Cash, Cash Equivalents and Short-Term Investments | 8.52M | 1.67M | 5.97M | 2.84M | 10.06M |
| Total Debt | 60.89K | 727.00K | 464.00K | 624.00K | 766.00K |
| Total Liabilities | 6.76M | 6.46M | 5.86M | 2.36M | 2.46M |
| Stockholders Equity | 11.38M | 8.32M | 4.68M | 3.16M | 10.45M |
Cash Flow | |||||
| Free Cash Flow | -5.40M | -13.04M | -7.09M | -7.11M | -6.33M |
| Operating Cash Flow | -5.39M | -12.26M | -6.83M | -7.05M | -6.01M |
| Investing Cash Flow | -658.25K | -598.00K | -265.00K | -220.00K | -278.00K |
| Financing Cash Flow | 12.77M | 8.56M | 10.23M | 47.00K | 8.80M |
Biodexa Pharmaceuticals Technical Analysis
Neutral
2.33
Price Trends
4.50
Negative
10.71
Negative
22.72
Negative
Market Momentum
-0.40
Negative
43.36
Neutral
43.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Neutral. The current price of 2.33 is below the 20-day moving average (MA) of 3.40, below the 50-day MA of 4.50, and below the 200-day MA of 22.72, indicating a neutral trend. The MACD of -0.40 indicates Negative momentum. The RSI at 43.36 is Neutral, neither overbought nor oversold. The STOCH value of 43.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BDRX.
Biodexa Pharmaceuticals Risk Analysis
Biodexa Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Biodexa Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Geopolitical risks could result in increased market volatility and uncertainty, which could negatively impact our business, financial condition and results of operation. Q4, 2023
Biodexa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $7.40M | -0.13 | -317.98% | ― | ― | 45.15% | |
47 Neutral | $9.51M | -0.10 | -262.78% | ― | ― | 84.04% | |
45 Neutral | $2.56M | ― | -82.17% | ― | -6.73% | 73.54% | |
43 Neutral | $1.49M | -0.19 | -63.03% | ― | ― | 88.07% | |
42 Neutral | $1.91M | -0.10 | -197.11% | ― | ― | 99.75% |
* Healthcare Sector Average
BDRX
Biodexa Pharmaceuticals
3.32
-71.18
-95.54%
INDP
Indaptus Therapeutics
3.43
-9.73
-73.94%
INM
InMed Pharmaceuticals
0.73
-2.22
-75.16%
ENVB
Enveric Biosciences
5.10
-11.22
-68.75%
CNSP
CNS Pharmaceuticals
2.29
-10.07
-81.47%
Biodexa Pharmaceuticals Corporate Events
Biodexa Pharmaceuticals Posts 2025 Preliminary Results and Deepens GI Cancer-Focused Pipeline
Mar 27, 2026
On March 27, 2026, Biodexa Pharmaceuticals reported its audited preliminary results for the year ended December 31, 2025, highlighting a completed strategic shift from drug delivery into a focused therapeutics business targeting gastrointestinal c...
Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance
Mar 18, 2026
On March 18, 2026, Biodexa Pharmaceuticals announced a change to the ratio of its American Depositary Receipts, shifting from one ADR representing 100,000 ordinary shares to one ADR representing 500,000 ordinary shares, effective on or about April...
Biodexa Licenses Otsuka’s Phase 1‑Ready Molecular Glue MTX240 for GIST
Feb 4, 2026
On February 4, 2026, Biodexa Pharmaceuticals announced it had entered into a license and collaboration agreement with Otsuka Pharmaceutical granting Biodexa an exclusive license, outside Japan, to develop, manufacture and commercialize OPB‑1...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.